Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer

Aaron M. Laine, Kenneth D. Westover, Hak Choy

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Locally advanced non-small cell lung cancer (LA-NSCLC) is a heterogeneous disease, encompassing stage IIIA, for which surgery in combination with chemotherapy and/or radiation therapy (RT) represents a potential treatment approach for select patients, and stage IIIB, for which chemoradiation represents the standard of care. Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with technologic innovations in radiotherapy have the potential to improve outcomes for this patient population. Many ongoing clinical trials use specific genetic mutations or histologic status to determine the combination of targeted therapies and RT, as well as to determine the optimal chemoradiotherapy platforms. Additionally, use of modern RT techniques has improved outcomes for some patients with limited metastatic disease, thereby prompting further studies on how to best integrate aggressive management of oligometastases using RT with chemotherapeutic regimens.

Original languageEnglish (US)
Pages (from-to)57-68
Number of pages12
JournalSeminars in Oncology
Volume41
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Therapeutics
Chemoradiotherapy
Standard of Care
Combination Drug Therapy
Clinical Trials
Mutation
Population

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. / Laine, Aaron M.; Westover, Kenneth D.; Choy, Hak.

In: Seminars in Oncology, Vol. 41, No. 1, 02.2014, p. 57-68.

Research output: Contribution to journalArticle

@article{f729beea9ba84dc690d90c9cdbb73b9a,
title = "Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer",
abstract = "Locally advanced non-small cell lung cancer (LA-NSCLC) is a heterogeneous disease, encompassing stage IIIA, for which surgery in combination with chemotherapy and/or radiation therapy (RT) represents a potential treatment approach for select patients, and stage IIIB, for which chemoradiation represents the standard of care. Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with technologic innovations in radiotherapy have the potential to improve outcomes for this patient population. Many ongoing clinical trials use specific genetic mutations or histologic status to determine the combination of targeted therapies and RT, as well as to determine the optimal chemoradiotherapy platforms. Additionally, use of modern RT techniques has improved outcomes for some patients with limited metastatic disease, thereby prompting further studies on how to best integrate aggressive management of oligometastases using RT with chemotherapeutic regimens.",
author = "Laine, {Aaron M.} and Westover, {Kenneth D.} and Hak Choy",
year = "2014",
month = "2",
doi = "10.1053/j.seminoncol.2013.12.012",
language = "English (US)",
volume = "41",
pages = "57--68",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer

AU - Laine, Aaron M.

AU - Westover, Kenneth D.

AU - Choy, Hak

PY - 2014/2

Y1 - 2014/2

N2 - Locally advanced non-small cell lung cancer (LA-NSCLC) is a heterogeneous disease, encompassing stage IIIA, for which surgery in combination with chemotherapy and/or radiation therapy (RT) represents a potential treatment approach for select patients, and stage IIIB, for which chemoradiation represents the standard of care. Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with technologic innovations in radiotherapy have the potential to improve outcomes for this patient population. Many ongoing clinical trials use specific genetic mutations or histologic status to determine the combination of targeted therapies and RT, as well as to determine the optimal chemoradiotherapy platforms. Additionally, use of modern RT techniques has improved outcomes for some patients with limited metastatic disease, thereby prompting further studies on how to best integrate aggressive management of oligometastases using RT with chemotherapeutic regimens.

AB - Locally advanced non-small cell lung cancer (LA-NSCLC) is a heterogeneous disease, encompassing stage IIIA, for which surgery in combination with chemotherapy and/or radiation therapy (RT) represents a potential treatment approach for select patients, and stage IIIB, for which chemoradiation represents the standard of care. Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with technologic innovations in radiotherapy have the potential to improve outcomes for this patient population. Many ongoing clinical trials use specific genetic mutations or histologic status to determine the combination of targeted therapies and RT, as well as to determine the optimal chemoradiotherapy platforms. Additionally, use of modern RT techniques has improved outcomes for some patients with limited metastatic disease, thereby prompting further studies on how to best integrate aggressive management of oligometastases using RT with chemotherapeutic regimens.

UR - http://www.scopus.com/inward/record.url?scp=84894440372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894440372&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2013.12.012

DO - 10.1053/j.seminoncol.2013.12.012

M3 - Article

C2 - 24565581

AN - SCOPUS:84894440372

VL - 41

SP - 57

EP - 68

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -